Ksilink’s pipeline of drug discovery programs

Truly patient-based

Ksilink’s coherent pipeline of drug discovery programs aims to deliver patient-based screenable disease models and first-in-class lead compounds to the pharmaceutical industry in the field of muscular disorders, diseases of the central nervous system (CNS), and oncology.

Ksilink is seeking to either spin-out or partner these programs in return for upfront payments, milestones and royalties.